Recent Finacing
Recent Raise
Bicara Therapeutics is a clinical-stage biotech developing bifunctional EGFR/TGF-β–targeting antibodies, advancing lead candidate BCA101 in Phase 1/1b trials for HNSCC, SqNSCLC, and cutaneous SCC.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
